Ballard Spahr represented Array BioPharma Inc. (Nasdaq: ARRY), in the recent closing of a public offering by the biopharmaceutical company, which generated total gross proceeds of…
Array BioPharma Inc.’s $259 Million Initial Public Offering
Ballard Spahr represented Array BioPharma Inc. (Nasdaq: ARRY), in the recent closing of a public offering by the biopharmaceutical company, which generated total gross proceeds of…